Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Vaxart clinical trials
The registry lists 29 studies whose lead sponsor is Vaxart or one of 3 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Vaxart.
- Vaxart23 studiesSame company
Something wrong?
- Biota Pharmaceuticals, Inc.4 studies →Acquired — became part of Vaxart, Feb 13, 2018 · source ↗
Something wrong?
- 1 study →
- 1 study →
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionActive, not recruitingNCT06672055Phase 2
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldCompletedNCT06944717Phase 1
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing InfantsCompletedNCT07254728Phase 1
- Norovirus Challenge StudyCompletedNCT05212168Phase 1/2
- A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersCompletedNCT05626803Phase 2
- A Ph 2 Trial With an Oral Tableted COVID-19 VaccineTerminatedNCT05067933Phase 2
- Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of SubjectsCompletedNCT04563702Phase 1
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersCompletedNCT05213728Phase 1
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesCompletedNCT04875676Phase 1/2
- Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus VaccineCompletedNCT04854746Phase 1
- A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccineCompletedNCT02918006Phase 2
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesCompletedNCT03897309Phase 1
- A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy VolunteersCompletedNCT02877264Phase 1
Sponsor listed in the registry: Aviragen Therapeutics · First submitted before Aviragen Therapeutics became part of Vaxart
- Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)CompletedNCT02830932Phase 1
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma PatientsCompletedNCT02724254Phase 2
- A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus InfectionCompletedNCT02367313Phase 2
Sponsor listed in the registry: Biota Pharmaceuticals, Inc. · First submitted before Biota Pharmaceuticals, Inc. became part of Vaxart
- Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus VaccineCompletedNCT02868073Phase 1
- Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy AdultsCompletedNCT02547792Phase 1
- A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy VolunteersCompletedNCT02101866Phase 1
Sponsor listed in the registry: Biota Pharmaceuticals, Inc. · First submitted before Biota Pharmaceuticals, Inc. became part of Vaxart
- Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital WartsCompletedNCT01532102Phase 1/2
Sponsor listed in the registry: Anaconda Pharma · First submitted before Anaconda Pharma became part of Vaxart
- Dose-Optimization Trial of VXA-G1.1-NN in Healthy VolunteersCompletedNCT03125473Phase 1
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy VolunteersCompletedNCT02668367Phase 1
Sponsor listed in the registry: Biota Pharmaceuticals, Inc. · First submitted before Biota Pharmaceuticals, Inc. became part of Vaxart
- Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy AdultsCompletedNCT03121339Phase 1
- Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy VolunteersCompletedNCT02558413Phase 1
Sponsor listed in the registry: Biota Pharmaceuticals, Inc. · First submitted before Biota Pharmaceuticals, Inc. became part of Vaxart
- A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus InfectionWithdrawnNCT03024177Phase 2
- Safety Study of an Oral Vaccine to Prevent Seasonal InfluenzaCompletedNCT01688297Phase 1
- Immunogenicity of ND1.1 by Delivery Directly to the IleumCompletedNCT01698060Phase 1
- Immunogenicity of Seasonal Influenza by Delivery Directly to IleumCompletedNCT01761123Phase 1
- Safety Study of an Oral Vaccine to Prevent Avian InfluenzaCompletedNCT01335347Phase 1